Welcome to our dedicated page for isr news (Ticker: isr), a resource for investors and traders seeking the latest updates and insights on isr stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect isr's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of isr's position in the market.
Isoray, Inc. (NYSE AMERICAN: ISR) announced its intent to conduct an underwritten public offering of common stock, with all shares to be sold by the Company. It will also grant underwriters a 30-day option to purchase an additional 15% of the shares. The offering is subject to market conditions. Isoray aims to use the net proceeds for operations, R&D, potential acquisitions, sales and marketing initiatives, and general corporate purposes. The offering is part of a shelf registration previously filed with the SEC.
Isoray, Inc. (NYSE American: ISR) announced that CEO Lori Woods will present at the H.C. Wainwright BioConnect 2021 Conference, scheduled for January 11-14, 2021. The on-demand presentation will be accessible on the company's Investor Relations webpage starting at 6:00 a.m. EDT on January 11, 2021, and will remain available for 90 days. Isoray is renowned for its innovation in seed brachytherapy, being the exclusive producer of Cesium-131 seeds, enhancing treatment options across various medical fields.
Isoray Medical, Inc. (NYSE American: ISR) has received FDA 510(k) clearance for C4 Imaging’s Sirius® MRI Markers, enhancing prostate cancer treatment with brachytherapy. This innovation allows for MRI-assisted localization of brachytherapy seeds, improving treatment accuracy and patient care. Isoray, the sole producer of Cesium-131 brachytherapy seeds, aims to advance therapeutic tools for prostate cancer. This partnership signifies a strategic advancement in the ongoing fight against prostate cancer, benefiting both patients and healthcare providers.
Isoray, Inc. (NYSE American: ISR) highlighted the effectiveness of its proprietary Cesium-131 treatment for prostate and brain cancers during presentations at the ASTRO 2020 annual meeting. Studies showed that Cesium-131 is a valuable option for patients with intermediate-risk prostate cancer and those with brain metastases. CEO Lori Woods expressed pride in the research efforts surrounding Cesium-131, emphasizing its potential benefits. The treatments demonstrate lower recurrence rates and complications compared to traditional methods, signaling a positive outlook for Cesium-131's role in oncology.
Isoray, Inc. (NYSE AMERICAN: ISR) reported a 3% year-over-year revenue increase for Q1 fiscal 2021, totaling $2.38 million. Non-prostate brachytherapy revenue surged 104%, while prostate brachytherapy revenue fell 9%. The net loss decreased 13% to $0.71 million, with basic and diluted EPS remaining at ($0.01). Operating expenses decreased 5% to $1.96 million, though R&D expenses rose 34%. Cash and equivalents reached $1.94 million, with no debt. A public offering generated gross proceeds of $9.50 million.
Isoray, Inc. (NYSE AMERICAN: ISR) will host a conference call on November 10, 2020, at 4:30 p.m. ET to discuss its financial results for the first quarter of fiscal 2021, which ended on September 30, 2020. The company will release its financial results after the close of U.S. markets on the same day. Investors can listen to the call by dialing (877) 407-8035 or access the webcast at this link, which will be available until November 10, 2021.
Isoray, Inc. (NYSE AMERICAN: ISR) announced the pricing of its public offering, issuing 18,269,230 shares plus warrants for 9,134,615 additional shares at $0.52 each. The total gross proceeds are estimated at $9.5 million, aimed at funding operations, R&D, acquisitions, and general corporate purposes. The warrants have an exercise price of $0.57 and expire in five years. Oppenheimer & Co. is the sole book-running manager for the offering, conducted under an effective shelf registration statement.
Isoray, Inc. (NYSE AMERICAN: ISR) announced its plans to conduct an underwritten public offering of common stock and warrants to raise funds. The offering's terms, including size, are subject to market conditions. Proceeds will support operations, research and development, acquisitions, sales and marketing initiatives, along with general corporate expenses. The offering will use a shelf registration statement filed with the SEC. Oppenheimer & Co. Inc. will manage the offering. Investors are advised to refer to the preliminary prospectus for detailed information.
Isoray, Inc. (NYSE AMERICAN: ISR) reported a strong fiscal fourth quarter and full-year results for the period ending June 30, 2020. Q4 revenue rose 18% to $2.28 million, with prostate brachytherapy contributing 84% of total revenue. The company experienced a 35% increase in new physician customers over the year. Gross profit margins improved to 47%, and the full-year revenue reached a record $9.68 million, up 32% from 2019. Despite a net loss of $1.19 million in Q4, the overall financial performance indicated positive growth trends, with guidance for Q1 2021 revenue projected between $2.3 million and $2.5 million.
Isoray, Inc. (NYSE American: ISR), a leader in medical technology, announced that CEO Lori Woods will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 23, 2020, at 1:40 p.m. ET. Alongside CFO Jonathan Hunt, they will conduct virtual meetings with institutional investors during the event. A live webcast of the presentation will be available on Isoray's Investor Relations page, with an on-demand replay accessible for 90 days post-presentation. Isoray specializes in Cesium-131 brachytherapy seeds, enhancing treatment options across medical disciplines.
FAQ
What is the market cap of isr (isr)?
